Owning your Development as an MSL

I interview Drew McGregor, Vice President, Head of Medical Affairs Excellence & Sustainability at Bayer. We discuss: How to balance patient focus with commercial objectives How to reduce silos across the organisation What would pharma look like without a separate MA strategy?

Interview with Sue Giordano - Head of Field Medical at Axsome Therapeutics. We discuss: What types of data are available to medical affairs?  What is the first step when choosing the type of data to show impact (asking the right question) What else needs to be kept in mind (cross functional communication) Can you provide some examples of how data (and which type of data) can be used to show MA impact (MSLs and impact on diagnosis code examples - pilot it first before widespread roll out) What type of competencies need to be in place for MA to successfully utilize data to show their impact?  How can these competencies be developed (in house v external)

Carlos Eid from Novartis shares his expertise on: The stakeholder engagement Journey Creating a seamless customer journey Starting with the patient Developing customer intimacy The types of data to collect along this engagement journey to assess if course correction is required.

I interview Raquel Washington, Executive Director Value Evidence Lead-Novartis US Medical. Raquel shares her experience on: - how Medical Science Liaisons (MSLs) can own their development - the steps required to progress in their careers - where to find those opportunities to grow and how to build relationships with those people in your network who will advocate for your growth. Raquel has had an incredible career in pharma so far and shares specific examples from her own pharma career and some of the challenges she overcame to get to where she is today.

Free Newsletter on Medical Affairs Excellence: https://dynamic-salad-157.myflodesk.com/lbyatyklzm Interview with Ross Baker, VP Medical Affairs at Vistagen Therapeutics. I ask Ross: What your week looks like as a VP medical affairs for a small biotech? What are the different functions you work with? As a senior leader - how do you make decisions? What advice would you have for people listening who interact with senior leadership? Working as a VP for a company with many pipeline products and fast track designations, would require a lot of prioritization skills - how do you prioritize what you/your teams should be focusing on?

Siddharth Jain - Medical Director, Global Medical Lead, at Takeda Rare Diseases shares his experience in: - What's the biggest difference from a medical affairs perspective working in rare diseases v non rare diseases? - Is it more difficult to find and engage KOLs in rare diseases? - What's the biggest challenge working in rare diseases from an MA perspective?

I Interview Scott Baver, VP Medical Affairs and we discuss building an MA department. 3 pillars in building an MA department: Community Engagement (HCPs/Payors) - who will we engage with & why? Evidence generation - over the lifecycle - what data do we need? Communication - pubs, building materials for congresses, MSLs etc.

MSL Consultant Newsletter: Sign up Here: https://view.flodesk.com/pages/63f6032d3e1e4ad28342cc69 I interview Angelyn Solko and we discuss congress planning. Specifically: What does congress planning involve? What do you need to keep in mind with booth design? Which stakeholders within pharma are involved in congress planning? Do you have to manage the budget? What is your role at the congress? What is your role post congress? What does a congress plan look like?

I interview Stacy Conner, National MSL Director at Abbvie. We discuss: How MSLs can read the room when with KOLs Why it's important to disagree with KOLs The power of asking clarifying questions How to move KOLs to a place of understanding When to educate and when to gather insights Sign up to the MSL Consultant newsletter here: https://view.flodesk.com/pages/63f6032d3e1e4ad28342cc69

Marcus West from 60seconds shares his experience on how to develop the skill of storytelling and apply it to clinical data and KOL meetings. We discuss: Important pillars of storytelling Why emotion is so important for engaging KOLs The hero's journey and how it can be related to clinical data This episode is sponsored by 60seconds. Learn more about 60seconds here: https://60seconds.com/